FABHALTA® (iptacopan) prescribing information (external link)
JAKAVI® (ruxolitinib) prescribing information (external link)
SCEMBLIX® (asciminib) prescribing information (external link)

This page includes promotional content created and funded by Novartis Pharmaceuticals UK Ltd. Novartis products may be mentioned.

 Haematology

FABHALTA®▼ (iptacopan)

HCP brochure

JAKAVI® (ruxolitinib)

JAKAVI dosing timeline

MF risk stratification

A guide to JAKAVI in PV

MF and PV educational modules

Patient symptom guide

MF essentials guide

PV essentials guide

jakavi-resources-video-tn

Video
4 mins 49 secs
Patient perspectives: “How MPN 10 helps me understand ‘my’ symptoms”

SCEMBLIX®▼ (asciminib)

HCP quality of life tracker

Support booklet for eligible patients prescribed SCEMBLIX

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.